Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is an American biopharmaceutical technology platform company headquartered in San Diego, California. The company's core business revolves around developing and commercializing innovative drug delivery solutions. Its mission is to enhance patient experiences and outcomes for both emerging and established therapies by enabling the subcutaneous administration of biologic treatments.

Halozyme's key offering is its proprietary ENHANZE® drug delivery technology, which utilizes recombinant human hyaluronidase PH20 (rHuPH20). This enzyme temporarily degrades hyaluronan in the extracellular matrix, facilitating the subcutaneous delivery of injected drugs and fluids, thereby converting traditional intravenous therapies into more convenient subcutaneous injections. The company licenses its ENHANZE technology to leading pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, and Bristol-Myers Squibb. Halozyme also maintains a portfolio of proprietary commercial products, including Hylenex® (hyaluronidase human injection) and XYOSTED® (testosterone replacement therapy). The company has expanded its drug delivery technology portfolio to include Hypercon™ and Surf Bio's hyperconcentration technologies.

Led by President and CEO Helen Torley, Halozyme recently announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. The company reported its first quarter 2026 financial results on May 11, 2026. Halozyme has also entered into a global collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon™ Technology. Positioned as a crucial partner to major pharmaceutical companies, Halozyme operates with a high-margin, royalty-driven business model, focusing on improving drug delivery and patient convenience.